What is a strong assessment and management plan for a patient presenting with hypertension?

Strong Assessment and Plan for Hypertension

Assessment

This patient has confirmed hypertension requiring immediate initiation of both lifestyle modifications AND pharmacological therapy—do not delay medication for a trial of lifestyle changes alone. 1

Diagnostic Confirmation

• Blood pressure elevation confirmed via office measurements and validated by out-of-office monitoring (home BP monitoring ≥135/85 mmHg or ambulatory BP monitoring daytime mean ≥130/80 mmHg) to exclude white-coat hypertension 1, 2
• Cardiovascular risk stratification completed using SCORE2 (ages 40-69) or SCORE2-OP (ages ≥70), identifying 10-year CVD risk and presence of high-risk features (established CVD, diabetes, CKD with eGFR <60, or hypertension-mediated organ damage) 1
• Secondary hypertension screening negative based on age >30 years, absence of resistant hypertension features, no sudden onset/worsening, and no suggestive clinical features 3, 1

Initial Workup Completed

• Laboratory assessment: Serum creatinine with eGFR calculation, urine albumin-to-creatinine ratio, fasting glucose, lipid profile (total:HDL cholesterol ratio), serum electrolytes (sodium, potassium), TSH 3, 1
• Cardiac evaluation: 12-lead ECG performed; echocardiography deferred unless ECG abnormalities or cardiac symptoms present 3, 1
• Fundoscopy: Not indicated unless BP >180/110 mmHg to evaluate for hypertensive emergency 1
• Target organ damage assessment: No evidence of hypertension-mediated organ damage (normal eGFR, no albuminuria, normal ECG) 1

Cardiovascular Risk Profile

• Overall CVD risk: [Specify: low/moderate/high based on SCORE2 calculation, presence of diabetes, CKD, or established CVD] 1
• Compelling indications identified: [Specify if diabetes, CKD with albuminuria, coronary artery disease, heart failure, or pregnancy planning present] 1

---

Plan

Blood Pressure Target

Target BP <130/80 mmHg (or <120-129/<80 mmHg if well-tolerated in most adults; stricter <130/80 mmHg for patients with diabetes, CKD, or established CVD) 1, 2, 4

Pharmacological Therapy (Initiated Immediately)

Start two-drug combination therapy as a single-pill combination to improve adherence and achieve BP control within 3 months: 1, 2

Preferred initial regimen for non-Black patients without compelling indications:

• ACE inhibitor (lisinopril 10-20 mg daily) OR ARB (losartan 50-100 mg daily) 5, 6
  • PLUS
• Dihydropyridine calcium channel blocker (amlodipine 5-10 mg daily) 1, 2
  • OR
• Thiazide-like diuretic (chlorthalidone 12.5-25 mg daily preferred over hydrochlorothiazide) 1, 2, 4

If compelling indications present, modify as follows:

• Diabetes: ACE inhibitor or ARB mandatory as first-line to reduce diabetic nephropathy progression 1, 5, 6
• CKD with albuminuria (UACR ≥30 mg/g): ACE inhibitor or ARB mandatory to reduce progressive kidney disease 1, 5, 6
• Coronary artery disease: ACE inhibitor or ARB first-line; add beta-blocker if history of myocardial infarction 1, 5
• Heart failure: Combination of ACE inhibitor/ARB, beta-blocker, diuretic, and mineralocorticoid receptor antagonist per heart failure guidelines 1
• Pregnancy or planning pregnancy: ABSOLUTE CONTRAINDICATION to ACE inhibitors and ARBs (cause fetal injury/death); use methyldopa, nifedipine, or labetalol instead 1

Lifestyle Modifications (Implemented Simultaneously with Medications)

Comprehensive lifestyle counseling initiated immediately (can lower systolic BP by 4-11 mmHg and enhances medication efficacy): 1, 2

• Dietary sodium restriction to <2 g/day (equivalent to ~5 g salt/day; eliminates table salt, avoids processed foods) reduces SBP by 5-8 mmHg 1, 2, 4
• DASH or Mediterranean diet: 8-10 servings/day fruits and vegetables, 2-3 servings/day low-fat dairy, whole grains, reduced saturated fat 1, 2, 4
• Potassium supplementation through dietary sources (fruits/vegetables) unless contraindicated by CKD 1
• Limit free sugar to <10% of energy intake, particularly avoiding sugar-sweetened beverages 1
• Weight reduction targeting BMI 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women); approximately 1 mmHg SBP reduction per 1 kg weight loss 1, 2, 4
• Aerobic exercise minimum 150 minutes/week (30 minutes, 5-7 days/week moderate-intensity) plus resistance training 2-3 times/week reduces SBP by 4-9 mmHg 1, 2
• Alcohol limitation to <100 g/week pure alcohol (≤2 drinks/day men, ≤1 drink/day women), with complete abstinence preferred 1, 2
• Complete tobacco cessation with referral to cessation programs mandatory 1, 2

Monitoring and Titration Strategy

• Monthly follow-up visits until BP target achieved within 3 months 1
• Recheck BP in 1 month after any medication change 1
• Monitor serum creatinine and potassium 1-2 weeks after initiating ACE inhibitor/ARB or diuretic, then periodically 1
• Home BP monitoring encouraged with validated devices for medication titration and adherence assessment 2
• If BP not controlled after 3 months on two-drug therapy: Add third agent from different class (typically the third component not yet used: CCB, ACE inhibitor/ARB, or thiazide diuretic) 1, 2

Resistant Hypertension Protocol (If Applicable)

If BP remains ≥130/80 mmHg on ≥3 medications at maximum tolerated doses (including diuretic): 3, 1, 2

1. Exclude pseudoresistance: Confirm with home BP monitoring or ambulatory monitoring, assess medication adherence, rule out white-coat effect 3, 7
2. Screen for interfering substances: NSAIDs, decongestants, stimulants, excessive alcohol, licorice, oral contraceptives 3, 7, 8
3. Optimize diuretic therapy: Switch to thiazide-like diuretic (chlorthalidone) if using hydrochlorothiazide; use loop diuretic if eGFR <30 ml/min/1.73m² or clinical volume overload 3, 8
4. Add spironolactone 25-50 mg daily as 4th-line agent if serum potassium <4.5 mmol/L and eGFR >45 ml/min/1.73m² 3, 7
5. Consider secondary hypertension workup: Primary aldosteronism (aldosterone-to-renin ratio), renovascular disease (renal artery duplex ultrasound), obstructive sleep apnea (sleep study), renal parenchymal disease (kidney ultrasound), pheochromocytoma (24-hour urine metanephrines) 3, 1, 7
6. Refer to specialist center with expertise in resistant hypertension management 3, 1

Patient Education and Adherence

• Explain cardiovascular risk reduction: 10 mmHg SBP reduction = 20-30% reduction in CVD events, 35-40% reduction in stroke, 20-25% reduction in myocardial infarction, 50% reduction in heart failure 2, 4
• Emphasize medication adherence: Single-pill combination therapy prescribed to improve adherence 1, 2
• Provide written lifestyle modification instructions with specific dietary and exercise targets 3, 1

Common Pitfalls to Avoid

• Do NOT delay pharmacotherapy for lifestyle modification trial alone—both must be initiated simultaneously 1, 2
• Do NOT use ACE inhibitors or ARBs in women of childbearing potential without reliable contraception due to teratogenicity 1
• Do NOT overlook medication non-adherence as the most common cause of apparent treatment failure 3, 7, 8
• Do NOT use excessive BP reduction in elderly patients (avoid SBP <120 mmHg if not well-tolerated) to prevent orthostatic hypotension and falls 1
• Do NOT forget to monitor potassium and creatinine 1-2 weeks after initiating ACE inhibitor/ARB or diuretic 1